OCA
XLRN

Octagon Capital Advisors’s Acceleron Pharma XLRN Stock Holding History

Octagon Capital Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-112,363
Closed -$14.1M – 37
2021
Q2 		$14.1M Hold
112,363
– – 2.92% 10
2021
Q1 		$15.2M Hold
112,363
– – 5.74% 5
2020
Q4 		$14.4M Buy
+112,363
New +$13.2M 4.98% 9

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Octagon Capital Advisors's XLRN Position: Q3 2021 in Review

Octagon Capital Advisors sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 112,363 shares — an estimated $14.1M sold.

Octagon Capital Advisors first reported a position in XLRN in Q4 2020 and held it in 3 quarters. The position peaked at $15.2M in Q1 2021. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

  • Octagon Capital Advisors reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
  • Octagon Capital Advisors sold 112,363 Acceleron Pharma shares in Q3 2021, an estimated $14.1M.
  • Octagon Capital Advisors first reported a position in Acceleron Pharma in Q4 2020 and held it in 3 quarters.
  • Octagon Capital Advisors's Acceleron Pharma position peaked at $15.2M in Q1 2021.
  • 330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Octagon Capital Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.